iCAD president and CEO Ken Ferry said that Xoft began the company’s relationship with UltraMed Technology three years ago, with the goal of expanding its IORT global footprint.

"Since that time, the partnership has grown and we hope to build on the momentum we have established with the UltraMed team to increase patient access to our IORT solution in Taiwan and in other Asian markets," Ferry added.

iCAD’s Xoft, a mobile and flexible therapy option, can reduce treatment times compared to whole breast radiation therapy for the treatment of early-stage breast cancer.

The Xoft system delivers a single, prescribed, targeted dose of isotope-free radiation when used for intraoperative radiation therapy, eliminating the need for a shielded treatment environment.